Skip to main content
. 2022 Sep 26;8(3):00213-2022. doi: 10.1183/23120541.00213-2022

TABLE 3.

Demographic and clinical characteristics of the participants in the Spanish registry of European Alpha-1 Research Collaboration with different pulmonary diseases

Variables Emphysema Bronchiectasis Asthma
Subjects (n) 163 83 55
Age (years) 61.2±11.7 62.5±11.5 45.8±16.4
Sex, male 96 (58.9) 41 (49.4) 24 (43.6)
BMI (kg·m−2) 26.7±5.1 26.8±4.4 26.4±5.3
Smokers 11 (6.7) 4 (4.8) 6 (10.9)
Ex-smokers 129 (79.1) 52 (62.7) 25 (45.5)
Never-smokers 23 (14.1) 27 (32.5) 24 (43.6)
Tobacco exposure (pack-years) 29.4±22.5 25.5±22 18.7±19
COPD 128 (78.5) 53 (63.9) 14 (25.5)
Emphysema 163 (100) 53 (63.9) 13 (23.6)
Bronchiectasis 53 (32.5) 83 (100) 8 (14.5)
Asthma 13 (8) 8 (9.6) 55 (100)
Liver disease 18 (11.2) 8 (9.6) 5 (9.1)
Age at onset of symptoms (years) 48.7±15.4 48.7±14.9 31.4±17.3
Age at diagnosis of AATD (years) 51.7±14.1 52.9±12.9 38.8±19
Index case 139 (85.3) 75 (90.4) 41 (74.5)
Family screening 21 (12.9) 8 (9.6) 10 (18.2)
Charlson index (age corrected) 3.9±1.7 3.9±1.6 2.3±2.1
Cardiovascular comorbidity # 58 (36.7) 28 (34.1) 9 (17)
FVC % pred 94.3±27.7 90.7±25.5 101±4
FEV1 % pred 59.6±27.5 67.7±28.7 86.3±27.9
FEV1/FVC % pred 49±15 58±16 69±17
KCO % pred 60.9±19.9 70.4±21.7 81.8±20.9
Augmentation therapy 95 (59.7) 38 (47.5) 8 (16)
AAT (mg·dL−1) 38.2±26.9 37.4±22.3 45.8±21.9
Number of exacerbations previous year 0.7±1.2 0.7±1.3 0.5±1.2
History of pneumonia 34 (21) 27 (32.5) 12 (23.1)
CAT 11.5 (7.7) 11 (7.8) 7 (6.4)
BODEx 2.3 (2) 1.7 (2) 1 (1.5)

Data presented as mean±sd or n (%), unless otherwise indicated. The different subgroups are not mutually exclusive. BMI: body mass index; COPD: chronic obstructive pulmonary disease; AATD: α1-antitrypsin deficiency; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; KCO: transfer coefficient of the lung for carbon monoxide; AAT: α1-antitrypsin; CAT: COPD Assessment Test; BODEx: BMI, Obstruction, Dyspnoea, Exacerbations index. #: cardiovascular disease includes hypertension, ischaemic heart disease, congestive heart failure and peripheral vascular disease.